Nilotinib is a classical c-Abl inhibitor that has been used in other neurodegenerative pathologies such as Parkinson’s disease (Pagan et al., 2019) and Alzheimer’s disease (Turner et al., 2020). This evidence concerns the gene ABL1 and Parkinson disease.